ARCHIVES

Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light

This article is from The Cancer Letter archive.

Vol. 40 No. 45 | December 5, 2014

Download PDF Visit The Full Archive

Related Articles

Niederhuber says his job is easy, but times are hard: NCI may need to cut up to $150 million.

December 9, 2005

Free Standing Cancer Center Firms Expanding Markets

February 21, 1986

Grant Review: NIH Names Members To New Clinical Oncology Review Panel

February 26, 1999

Stronger Federal Role Needed To Improve Palliative Care.

June 22, 2001

“Sloppy” Searle Studies Described By FDA At Kennedy Hearing; Rauscher “Outraged”

January 23, 1976

US Oncology Begins Trial Of Taxotere And Xeloda

September 27, 2002